Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
To determine the primary end point response rate of the combinations of Gemcitabine and
Oxaliplatin (Gem-Ox) in the treatment of hepatocellular carcinoma (HCC) in patients with
platelet counts greater 100,000 per microliter in a single arme Phase II trial.
To determine the toxicity profile of this regimen To determine the effect of this treatment
on patient survival, time to treatment failure, time ot progression, time to response.